Public Companies
Universal Ibogaine Announces Results of Annual General Meeting
Universal Ibogaine Inc.(TSXV:IBO), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, is pleased to announce…
Universal Ibogaine Inc.(TSXV:IBO), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, is pleased to announce that all resolutions were passed by the requisite majority of shareholders at its annual general meeting which was held on October 3, 2022 in Vancouver, BC.
UI’s five incumbent directors, Ian Campbell, Anthony DeCristofaro, Nicholas Karos, Dr. Alberto Sola Agullo, and Robert Turner were re-elected by shareholders to the Company’s Board of Directors. The shareholders also approved the re-appointment of Deloitte LLP as auditors of the Company for the ensuing year, and approved the Company’s 2021 Stock Option Plan, the Company’s 2022 Equity Incentive Compensation Plan (the “EICP”) and the Company’s 2022 Stock Option Plan (the “2022 SOP”).
As disclosed in the Company’s August 25, 2022 Management Information Circular for the AGM, shareholders were requested to approve replacing the former 2021 Stock Option Plan (which had a 20% fixed cap) with the new EICP (which will have a 10% fixed cap) and the new 2022 SOP (which will have a 10% floating cap). The terms of the EICP and the 2022 SOP are also subject to approval by the TSX Venture Exchange. A copy of each of the Company’s 2021 Stock Option Plan, the EICP and the 2022 SOP are included in the Info.
About Universal Ibogaine Inc
UI is a life sciences company, with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that protocol globally through planned future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.
-
Psychedelics1 week ago
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Psilocybin1 week ago
Are Shrooms Legal in Oregon: Full Guide
-
Law & Regulation1 week ago
Going concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Law & Regulation1 week ago
Numinus reports declining revenue as the company restructures
-
Psychedelics1 week ago
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics1 week ago
Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Psychedelics1 week ago
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Law & Regulation6 days ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights